12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Vytacera Pharma Inc., University of Minnesota deal

The university granted newco Vytacera exclusive, worldwide rights to develop and commercialize cyanide poisoning treatment Sulfanegen. The prodrug of 3-mercaptopyruvate (3-MCP)...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >